AbbVie Raises Guidance Based On Humira Patent Umbrella
This article was originally published in Scrip
Executive Summary
Analyst buzz about the AbbVie Inc. third quarter earnings call Oct. 30 centered on its strongly optimistic sales guidance through 2020, based on its belief in a suite of intellectual property that it says will protect top-seller Humira from US biosimilar competition until 2022 or later.